Clinical Trial Update: Role of ARNi in Ventricular Remodeling in Hypertensive LVH [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating whether an angiotensin receptor-neprilysin inhibitor can influence ventricular remodeling in patients with hypertensive left ventricu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertensive Heart Disease
• Left Ventricular Hypertrophy

Drugs mentioned

• Entresto (sacubitril/valsartan) (sacubitril/valsartan)

Snippet

Sponsor: National Heart Centre Singapore | Conditions: Hypertensive Heart Disease | Phase 2 | Status: COMPLETED